摘要
目的探讨经鼻吸入布地奈德治疗过敏性鼻炎-哮喘综合征(CARAS)的疗效及安全性。方法 82例CARAS急性发作期患者,随机分为2组,均采用口-鼻两用雾化罐。经鼻组(n=40)和经口组(n=42)分别经鼻和经口吸入布地奈德气雾剂,均每次1吸200μg,早晚各1次,连续治疗8 wk。观察治疗前后症状评分、第一秒用力呼气容积(FEV_1)、呼气峰流量(PEF)、血清总IgE、嗜酸粒细胞(EOS)绝对值的变化。结果治疗后2组鼻部及胸部症状评分、血清总IgE水平、EOS绝对值均下降(P<0.01),经鼻组症状评分、总IgE水平低于经口组(P<0.05或P<0.01),2组EOS绝对值无显著差异(P>0.05)。2组FEV_1、PEF水平均升高(P<0.01),经鼻组FEV_1、PEF水平均高于经口组(P<0.01)。2组均无严重不良反应发生。结论经鼻吸入布地奈德可有效改善CARAS患者症状及肺功能、降低血清总IgE水平,疗效优于经口吸入,且不良反应少。
AIM To explore the effect and safety of budesonide inhalation by nose on combined allergic rhinitis and asthma syndrome （CARAS）. METHODS Eighty-two patients with CARAS were randomly divided into two groups. All patients were treated by atomization pots. The patients in the nose group （n = 40） received budesonide aerosol by nose-suction nozzle, while the others in the mouth group （n = 42） received budesonide aerosol by mouth-suction nozzle. The doses of the two groups were the same and the courses were both 8 weeks. The symptoms scorings, lung function （FEV1, PEF）, were observed before and after the treatment. RESULTS levels of serum total IgE and eosinophil absolute values The symptoms scorings of nasal and thorax, the levels of IgE, and the eosinophil absolute values in both groups decreased obviously after the treatment （P 〈 0.01）. The symptoms scorings and the level of IgE in the nose group were obviously lower than those in the mouth group（P 〈 0.05 or P 〈 0.01）, while no significant difference in the eosinophil absolute values between two groups （P 〉 0.05）. The levels of FEV1 and PEF increased significantly in both groups, and those in the nose group were higher （P 〈 0.01） . There was no severe adverse reaction in the two groups. CONCLUSION Budesonide inhalation by nose in treating CARAS can obviously improve symptoms and lung functions, reduce serum total IgE level, with few adverse reaction. Budesonide inhalation by nose is superior to inhalation by mouth.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2012年第12期752-755,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
布地奈德
投药
吸入
鼻炎
哮喘
过敏性鼻炎-哮喘综合征
budesonide
administration, inhalation
rhinitis
asthma
combined allergic rhinitis andasthma syndrome
